Table of Contents Author Guidelines Submit a Manuscript
Research Article
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 1913954, 1 page
https://doi.org/10.1155/2017/1913954
Corrigendum

Corrigendum to “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway”

1Division of Nephrology, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea
2Clinical Research Institute, Daejeon St. Mary’s Hospital, Daejeon, Republic of Korea

Correspondence should be addressed to Hyeon Seok Hwang; rk.ca.cilohtac@shgnawh

Received 6 June 2017; Accepted 2 July 2017; Published 13 August 2017

Copyright © 2017 Yu Ah Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the article titled “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway” [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).

References

  1. Y. A. Hong, K. J. Yang, S. Y. Jung et al., “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5031926, 17 pages, 2017. View at Publisher · View at Google Scholar